Oncology

Financial toxicity can lead to worse long-term outcomes and psychological distress among patients with breast cancer.

Rami Komrokji, MD, discusses whether the majority of patients in the MOST study were being treated at the time of enrollment, and why real-world data is so essential.

The specialty drug pipeline is coming off a strong year, and the oncology pipeline has a wealth of potential oncolytics.

Rami Komrokji, MD, discusses common prior treatments of low-risk and intermediate-1 risk patients in the MOST study.

Study shows the mortality rate among breast cancer survivors is lower among those who received fertility preservation.

The cost of oncology treatment is high and rising in the United States.

Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute speaks about why data are limited in myelofibrosis.

In an interview with Pharmacy Times, Helen Thackray, MD, Thackray describes what she hopes to see for future trials involving sickle cell disease and rivipansel for acute vaso-occlusive crisis.

In an interview with Pharmacy Times, Helen Thackray, MD, Thackray emphasizes the importance of administering rivipansel early in vaso-occlusive crisis and how it is meaningful for both adults and children with sickle cell disease.

Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute speaks about factors in treatment decisions for patients with myelofibrosis.

Data from a preliminary phase 1b/2 study demonstrated a single low-dose infusion of ciltacabtagene autoleucel resulted in early, deep, and durable responses in heavily pretreated patients with multiple myeloma.

MEDI2228, an ADC that targets the extracellular domain of human BCMA, demonstrated clinical efficacy at all dose levels in treating patients with relapsed/refractory multiple myeloma.

Trials confirm patients with chronic lymphocytic leukemia treated with venetoclax-based regimens achieve higher rates of undetectable minimal residual disease, which may be associated with a lower risk of future disease progression or death.

Although postoperative radiation therapy affected the risk of local recurrence of breast cancer, it did not significantly impact certain other clinical outcomes, including distant metastasis and recurrence in the opposite breast.

The higher risk of delivery and fetal complications suggests that physicians should more closely monitor pregnant breast cancer survivors.

Session at at the San Antonio Breast Cancer Symposium featured several abstract presentations on disparities in health care access in breast cancer, including research on the necessity of avoiding a one-size-fits-all approach to medicine.

Younger and Black patients are more likely to experience breast cancer symptom under-recognition.

Overdiagnosis of breast cancer can lead to unnecessarily aggressive treatments and mastectomies.

In an interview with Pharmacy Times, Helen Thackray, MD, reveals what finding she believes was the most interesting after analyzing the results of the RESET clinical trial, which covers the early initiation with rivipansel for acute vaso-occulusive crisis in sickle cell disease.

A new combination therapy cleanses the colon before this important procedure that screens for colorectal cancer, the third-leading cause of cancer-related deaths in the United States.

There were significant modifications in breast cancer treatment due to the coronavirus disease 2019 pandemic, such as high rates of NET chemotherapy, genomic assay testing on core biopsies, and delays in planned surgeries.

Tesetaxel is a novel, oral taxane with several unique properties being investigated for use in patients with HER2-negative, HR-positive metastatic breast cancer.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses closing thoughts on the results of the study and its implications for future treatment options for patients with relapsed/refractory multiple myeloma.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses what the implications of the high rate of dose holds that occurred in the study were, and whether there any plans to address this concern in the future.

Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what his team’s plans are for the evaluation of ponatinib during the remaining portion of the OPTIC trial, which is currently ongoing.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses whether the treatment emergent adverse events (AEs) were consistent with the known safety profiles for belantamab mafodotin and pomalidomide.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses common adverse events (AEs) observed in patients with relapsed/refractory multiple myeloma following treatment with belantamab mafodotin in combination with pomalidomide and dexamethasone.

Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what the interim analysis of the OPTIC trial demonstrated in terms of the safety and arterial occlusive events profiles with response-based ponatinib dosing regimens.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses the common prior therapies for patients with relapsed/refractory multiple myeloma who were enrolled in the ALGONQUIN trial.

Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what the PACE trial was able to demonstrate in regard to patient response to ponatinib for patients with resistant and intolerant chronic-phase CML with substantial prior second-generation treatment.